JP2007534615A5 - - Google Patents

Download PDF

Info

Publication number
JP2007534615A5
JP2007534615A5 JP2006517744A JP2006517744A JP2007534615A5 JP 2007534615 A5 JP2007534615 A5 JP 2007534615A5 JP 2006517744 A JP2006517744 A JP 2006517744A JP 2006517744 A JP2006517744 A JP 2006517744A JP 2007534615 A5 JP2007534615 A5 JP 2007534615A5
Authority
JP
Japan
Prior art keywords
did2
fragment
scd4
domains
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006517744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007534615A (ja
Filing date
Publication date
Priority claimed from US10/612,192 external-priority patent/US20040076636A1/en
Application filed filed Critical
Publication of JP2007534615A publication Critical patent/JP2007534615A/ja
Publication of JP2007534615A5 publication Critical patent/JP2007534615A5/ja
Pending legal-status Critical Current

Links

JP2006517744A 2003-07-02 2004-06-28 Ｈｉｖ免疫原性複合体 Pending JP2007534615A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/612,192 US20040076636A1 (en) 1993-05-07 2003-07-02 HIV immunogenic complexes
PCT/US2004/020757 WO2005019248A1 (en) 2003-07-02 2004-06-28 Hiv immunogenic complexes

Publications (2)

Publication Number Publication Date
JP2007534615A JP2007534615A (ja) 2007-11-29
JP2007534615A5 true JP2007534615A5 (enExample) 2010-11-04

Family

ID=34216272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006517744A Pending JP2007534615A (ja) 2003-07-02 2004-06-28 Ｈｉｖ免疫原性複合体

Country Status (5)

Country Link
US (1) US20040076636A1 (enExample)
EP (1) EP1638996A1 (enExample)
JP (1) JP2007534615A (enExample)
CA (1) CA2530821A1 (enExample)
WO (1) WO2005019248A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025276A2 (en) * 2005-08-25 2007-03-01 Government Of The United States Of America, As Represented By The Secretary Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies
CA2626257A1 (en) * 2005-10-17 2007-04-26 Novartis Ag Multiclade hiv vaccines
CN107955815B (zh) * 2017-11-30 2019-06-11 山东兴瑞生物科技有限公司 抗hiv-1基因、该基因的应用、具有该基因的dc疫苗及疫苗制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843454A (en) * 1993-05-07 1998-12-01 Akzo Nobel N.V. HIV immunogenic complexes
PT1137786E (pt) * 1999-10-08 2007-07-13 Univ Maryland Biotech Inst Quimeras de proteína do invólucro/receptor de vírus e métodos de utilização.
US6908612B2 (en) * 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
GB0218817D0 (en) * 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
Zolla-Pazner et al. Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design
Ferrantelli et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies
JP2023531990A5 (enExample)
JP2023531705A5 (enExample)
WO2003033666A3 (en) Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
WO2010043977A3 (en) Dengue virus neutralizing antibodies and uses thereof
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
PL1639011T3 (pl) Pegilowane przeciwciała jednodomenowe (dAb)
JP2004248677A5 (enExample)
WO2003089593A3 (en) Adjuvant enhanced immunotherapy
JP2006519228A5 (ja) 抗原に対し霊長類を免疫寛容化する抗体の使用法
JP2009509970A5 (enExample)
Rubens et al. HIV vaccine: recent advances, current roadblocks, and future directions
WO2005030806A3 (en) Norovirus monoclonal antibodies and peptides
JP2016503059A5 (enExample)
WO2006050219A3 (en) Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
JP2007513976A5 (enExample)
NZ515356A (en) Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5
EP1700122A4 (en) IMMUNOASSAYS, HAPTENE, IMMUNOGENES AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS
Chen et al. Reintroduction of the 2G12 epitope in an HIV-1 clade C gp120
Cheedarla et al. Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals
Visciano et al. Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate
WO2002026785A3 (de) Cd4+ t-lymphozyten spezifische hepatitis c virus-epitope
WO2007112079A3 (en) Multivalent immunogen
EP3636668A3 (en) Immunoglobulins directed to bacterial viral and endogenous polypeptides